KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments (2018 - 2023)

Historic Change in Acquisitions & Divestments for Esperion Therapeutics (ESPR) over the last 5 years, with Q2 2023 value amounting to $17.5 million.

  • Esperion Therapeutics' Change in Acquisitions & Divestments rose 25000.0% to $17.5 million in Q2 2023 from the same period last year, while for Mar 2024 it was $17.5 million, marking a year-over-year decrease of 8118.3%. This contributed to the annual value of $42.5 million for FY2023, which is 3750.09% down from last year.
  • As of Q2 2023, Esperion Therapeutics' Change in Acquisitions & Divestments stood at $17.5 million, which was up 25000.0% from $25.0 million recorded in Q1 2023.
  • In the past 5 years, Esperion Therapeutics' Change in Acquisitions & Divestments registered a high of $45.9 million during Q1 2019, and its lowest value of $2.2 million during Q3 2020.
  • Its 4-year average for Change in Acquisitions & Divestments is $20.8 million, with a median of $23.3 million in 2019.
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Acquisitions & Divestments tumbled by 8961.94% in 2020, and later skyrocketed by 25000.0% in 2023.
  • Over the past 4 years, Esperion Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $5.0 million in 2019, then plummeted by 55.0% to $2.2 million in 2020, then soared by 1233.38% to $30.0 million in 2022, then tumbled by 41.67% to $17.5 million in 2023.
  • Its Change in Acquisitions & Divestments was $17.5 million in Q2 2023, compared to $25.0 million in Q1 2023 and $30.0 million in Q4 2022.